Proliferation News and Research

RSS

Targeted immune cells shrink tumors in mice

Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice.

10 Feb 2009

FDA approves clinical studies of novel anti-cancer drug developed by Italian researchers

Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel antitumoral agent.

10 Feb 2009

New drug short-circuits cancer growth

A new drug that blocks cancer's main source of growth has been created in the lab and proven effective in mice, scientists are reporting.

10 Feb 2009

New understanding of blinding degenerative eye conditions

Though based on mouse studies, the research bolsters the idea that humans suffering from these and other eye conditions may be able to help preserve function by adding antioxidants to their diet, and explains why this would work.

8 Feb 2009

Hair follicle stem cells may be key to organ regeneration

Most people consider hair as a purely cosmetic part of their lives. To others, it may help uncover one of nature's best-kept secrets: the body's ability to regenerate organs.

8 Feb 2009

New clues to pancreatic cells' destruction in diabetes

Researchers have found what appears to be a major culprit behind the loss of insulin-producing beta cells from the pancreases of people with diabetes, a critical event in the progression of the disease.

3 Feb 2009

New inhibitors could be new class of cancer drugs

A team of Vanderbilt University Medical Center investigators has developed a group of chemical compounds that could represent a new class of drugs for treating cancer.

3 Feb 2009

Stat3 signaling tips the balance of immunity in favor of cancer

New research reveals how a cancer-associated protein enables tumor cells to evade the immune system by both suppressing antitumor influences and promoting tumor-enhancing conditions, in essence turning the immune system to the dark side of the force.

2 Feb 2009

New potential targets for colitis-associated cancer

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine - the first researcher to demonstrate a molecular link between inflammation and cancer - has identified two potential targets for the prevention and treatment of colitis-associated cancer (CAC), the most serious complication of inflammatory bowel disease.

2 Feb 2009

Rare skin tumor responds better to treatment thanmelanoma

University of Michigan Health System researchers have published new data to help answer two dreaded questions: "Is it cancer?" and "What type of treatment should I have?"

2 Feb 2009

Stress may speed growth of melanoma tumors

For patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.

2 Feb 2009

Discovery of new class of non-protein coding genes in mammals with key functions

A research team at the Broad Institute of Harvard and MIT and Beth Israel Deaconess Medical Center has uncovered a vast new class of previously unrecognized mammalian genes that do not encode proteins, but instead function as long RNA molecules.

2 Feb 2009

Inflammation contributes to colon cancer

Researchers led by Drs. Lillian Maggio-Price and Brian Iritani at The University of Washington found that mice that lack the immune inhibitory molecule Smad3 are acutely sensitive to both bacterially-induced inflammation and cancer.

21 Jan 2009

Large DNA stretches, not single genes, shut off as cells mature

Experiments at Johns Hopkins have found that the gradual maturing of embryonic cells into cells as varied as brain, liver and immune system cells is apparently due to the shut off of several genes at once rather than in individual smatterings as previous studies have implied.

19 Jan 2009

Researchers find novel use for old compound in cancer treatment

The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.

19 Jan 2009

Theraputic target for prostate cancer

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

14 Jan 2009

Discovery of new regulatory circuit controlling immune cell production in mice

Using a mouse model, researchers have shown that elevated levels of a small protein known as interleukin 7 (IL-7) plays a central role in regulating the production of a type of white blood cell that is required for effective immune responses.

12 Jan 2009

Maslinic acid from olive-skin pomace protects against colon cancer

Researchers from the University of Granada and the University of Barcelona have shown that treatment with maslinic acid, a triterpenoid compound isolated from olive-skin pomace, results in a significant inhibition of cell proliferation and causes apoptotic death in colon-cancer cells.

8 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009